- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00185874
Phase I Intratumoral Dendritic Cell Immunotherapy in Thermally Ablated Liver Metastases
January 11, 2010 updated by: Stanford University
A Phase I Trial of Intratumoral Dendritic Cell Immunotherapy in Thermally Ablated Liver Metastases
Up to twenty-two patients will be enrolled in this study to receive autologous dendritic cells (DCs) administered intratumorally into liver metastases following radiofrequency thermal ablation of those lesions.
Patients will receive two vaccinations of DCs at monthly intervals.
A dose escalation study of DCs will be included in this study in an attempt to define the maximum tolerated dose of administered DCs.
Study Overview
Status
Terminated
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Anticipated)
22
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
California
-
Stanford, California, United States, 94305
- Stanford University School of Medicine
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:- Patients must have a histologically confirmed colorectal or neuroendocrine cancer with two or more hepatic metastatic lesions.
Patients must have unresectable liver metastasis by virtue of:
- Bi-lobar disease.
- Extra-hepatic disease.
- Patients for whom there are medical contraindications to surgery.
- Anatomic sites within the liver that in the opinion of our surgeon would likely be left with positive margin.
- Patient must have a minimum of 2 RFA-eligible lesion in the liver. Such as hepatic lesions that are 5 cm or smaller and that are accessible to RF ablation, which in general excludes sites contiguous with critical structures such as bowel or central bile duct and also those that are not amenable to radiographic localization such as small lesions in the dome of the liver. Extra-hepatic disease will be allowed provided that the liver lesions represent the most life-threatening site for that patient. Examples include sub centimeter asymptomatic lung metastases or asymptomatic retroperitoneal lymph nodes or peritoneal metastases
- Evaluable disease by CT scan or MRI in addition to the lesions to be treated with RFA.
- More than 4 weeks must have elapsed from the time of major surgery or completion of the last dose of chemotherapy, radiation therapy, investigational therapy and patients must adequately recover from these effects.
- Life expectancy of >3 months.
- Karnofsky performance status >70%.
Patients must have normal organ and marrow functions as defined below:
- absolute neutrophil count >1,500/mm^3
- platelets >70,000/mm^3
- total bilirubin <1.5 mg/dL
- AST(SGOT)/ALT(SGPT) <2.5 X institutional upper limit of normal
- creatinine within normal institutional limits OR
- creatinine clearance >60mL/min/1.73 m^2 for patients with creatinine levels above institutional normal.
- albumin > 2.8 mg/dL
- Patients must have adequate clotting function (platelet > 70k; INR<1.4; PTT<60).
- Age >18 years.
- The effects of DCs on the developing human fetus are unknown. For this reason, women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control) prior to study entry and for the duration of study participation. Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately.
- No history of autoimmune diseases.
- Ability to understand the willingness to sign a written informed consent document. Exclusion Criteria:- Patients may not be receiving anticoagulation therapy.
- Patients may not be receiving any other investigational agents.
- Patients with known brain metastases will be excluded because of their poor prognosis and because they often develop progressive neurological dysfunction that would confound the evaluation of neurological and other adverse effects.
- Uncontrolled concurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situation that would limit compliance with study requirements.
- Patients with a history of portal hypertension, cirrhosis/hepatitis, or with radiographic evidence of cirrhosis and/or varices are at high risk for developing a complication when undergoing a liver biopsy and may be excluded at the investigators' discretion from participation in this protocol.
- Patients who test positive for Hepatitis B virus, Hepatitis C virus or HIV.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
To determine the feasibility of harvesting autologous dendritic cells (DC) for CT-guided intratumoral DC injection
Time Frame: NA- study terminated
|
NA- study terminated
|
To establish the maximally tolerated dose (MTD) and dose limiting toxicity (DLT) of intratumoral autologous dendritic cell vaccination in combination with radiofrequency ablation (RFA) of liver metastases.
Time Frame: NA- study terminated
|
NA- study terminated
|
To determine the toxicity of this regimen
Time Frame: NA- study terminated
|
NA- study terminated
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
To determine the activity of this regimen as determined by tumor marker response, pathologic response and radiographic response of treated lesions.
Time Frame: NA- study terminated
|
NA- study terminated
|
To evaluate the immune response of patients treated with RFA + DC based on the presence and characterization of tumor infiltrating white blood cells
Time Frame: NA- study terminated
|
NA- study terminated
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Principal Investigator: Edgar G Engleman, Stanford University
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
January 1, 2004
Primary Completion (Actual)
October 1, 2007
Study Completion (Actual)
October 1, 2007
Study Registration Dates
First Submitted
September 12, 2005
First Submitted That Met QC Criteria
September 12, 2005
First Posted (Estimate)
September 16, 2005
Study Record Updates
Last Update Posted (Estimate)
January 13, 2010
Last Update Submitted That Met QC Criteria
January 11, 2010
Last Verified
January 1, 2010
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- HEP0002
- NCT00185874
- NIH 16766
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Liver Cancer
-
Slawa CwajnaNova Scotia Health AuthorityWithdrawnPrimary Liver Cancer | Metastatic Liver CancerCanada
-
Duke UniversityCompletedPrimary Liver Cancer | Metastatic Liver Cancer From Any Cancer SiteUnited States
-
University of HawaiiGlaxoSmithKlineRecruitingAdvanced Adult Primary Liver Cancer | Localized Unresectable Adult Primary Liver Cancer | Adult Primary Liver CancerUnited States
-
Célia TurcoCompletedPrimary Liver Cancer | Liver Metastases | Secondary Liver CancerFrance
-
University of CincinnatiActive, not recruitingLiver Metastases | Advanced Adult Primary Liver Cancer | Localized Unresectable Adult Primary Liver Cancer | Recurrent Adult Primary Liver CancerUnited States
-
Lisa H. Butterfield, Ph.D.National Cancer Institute (NCI)TerminatedHepatocellular Carcinoma | Liver Cancer | Cancer of Liver | Hepatoma | Hepatocellular Cancer | Hepatic Cancer | Liver Cell Carcinoma | Cancer, Hepatocellular | Liver Cancer, Adult | Liver Cell Carcinoma, Adult | Cancer of the Liver | Neoplasms, Liver | Hepatic Neoplasms | Neoplasms, HepaticUnited States
-
Radboud University Medical CenterTerumo Medical CorporationCompletedPrimary Liver Cancer | Liver Cancer | Liver Metastasis Colon CancerNetherlands
-
Cardiovascular and Interventional Radiological...RecruitingPrimary Liver Cancer | Secondary Liver CancerGermany
-
Shanghai Huihe Medical Technology Co., LtdEnrolling by invitation
-
Burzynski Research InstituteTerminatedPrimary Liver CancerUnited States
Clinical Trials on autologous dendritic cells
-
Fundació Sant Joan de DéuInstitut d'Investigacions Biomèdiques August Pi i SunyerUnknownDiffuse Intrinsic Pontine GliomaSpain
-
Ever Supreme Bio Technology Co., Ltd.Recruiting
-
Jonsson Comprehensive Cancer CenterKite, A Gilead CompanyCompletedClear Cell Renal Cell Carcinoma | Stage IV Renal Cell Cancer | Recurrent Renal Cell CancerUnited States
-
Massachusetts General HospitalNational Institute of Allergy and Infectious Diseases (NIAID)CompletedHIV Infections | HIV-1 InfectionUnited States
-
Radboud University Medical CenterRotterdam Eye HospitalTerminated
-
Statens Serum InstitutRigshospitalet, Denmark; Hvidovre University HospitalCompleted
-
The Catholic University of KoreaRecruitingMyocardial InfarctionKorea, Republic of
-
Clinica Universidad de Navarra, Universidad de...CompletedGlioblastoma MultiformeSpain
-
Cedars-Sinai Medical CenterCompletedGlioblastoma | Brain Stem GliomaUnited States
-
Erasmus Medical CenterCompleted